Electromed Inc. (ELMD) Cut to “Sell” at Zacks Investment Research

electromed-inc-elmd-cut-to-8220sell8221-at-zacks-investment-research.jpg

Electromed Inc. (NYSEMKT:ELMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.
According to Zacks, “Electromed, Inc. manufactures, markets and sells products that provide airway clearance therapy to patients with compromised pulmonary function. The Company is the designer, manufacturer and worldwide provider of the SmartVest® Airway Clearance System and related products. The patented system uses High Frequency Chest Wall Oscillation (HFCWO), an alternative to Chest Physiotherapy (CPT), to deliver airway clearance treatment. The Company manufactures its products for use by chronically-ill patients who face health risks due to pneumonia and mucus accumulation in the lungs, particularly patients with cystic fibrosis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and neuro-muscular disorders. The purpose of its primary product, the SmartVest System, is to loosen, mobilize, and release respiratory secretions from the lungs. The Company’s products are primarily used in the home health care market and in hospitals. Electromed, Inc. is headquartered in New Prague, Minnesota. “
Electromed (NYSEMKT:ELMD) traded up 7.19% during trading on Monday, reaching $4.92. The company’s stock had a trading volume of 414,641 shares. The firm has a market cap of $40.43 million, a P/E ratio of 18.22 and a beta of 0.89. Electromed has a 52 week low of $1.55 and a 52 week high of $6.26. The stock’s 50 day moving average is $4.68 and its 200-day moving average is $4.39.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/electromed-inc-elmd-cut-to-sell-at-zacks-investment-research.html

Electromed (NYSEMKT:ELMD) last announced its earnings results on Tuesday, September 6th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.05 by $0.01. The firm earned $5.70 million during the quarter. On average, equities research analysts forecast that Electromed will post $0.35 earnings per share for the current fiscal year.
Several institutional investors have recently modified their holdings of the stock. Barclays PLC purchased a new position in shares of Electromed during the first quarter valued at about $117,000. Acrospire Investment Management LLC bought a new position in Electromed during the first quarter valued at $135,000. Finally, Renaissance Technologies LLC bought a new position in Electromed during the first quarter valued at $401,000.
Electromed Company Profile
Electromed, Inc, is a pharmaceutical company. The Company manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System (SmartVest System) includes its newest generation SmartVest SQL and previous generation SV2100 and related products, to patients with compromised pulmonary function.

Receive News & Ratings for Electromed Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Electromed Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Electromed Inc. (ELMD) Cut to “Sell” at Zacks Investment Research"

Leave a comment

Your email address will not be published.

*